Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceNAGE +0.16%68 Debt-to-Equity is 0.03 as of Jun. 2026, which is 63% below its 10-year median of 0.08. GuruFocus rates NAGE with a GF Score™ of 68/100 and a GF Value™ of $4.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 956 Biotechnology companies, Niagen Bioscience ranks better than 80.65% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Niagen Bioscience's Debt-to-Equity or its related term are showing as below:
NAGE'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.81
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Niagen Bioscience was 0.81. The lowest was 0.01. And the median was 0.08.
NAGE's Debt-to-Equity is ranked better than 80.65% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs NAGE: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Niagen Bioscience Debt-to-Equity Related Terms
Niagen Bioscience Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAGE vs CAMP, ALEC, ELDN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Niagen Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (NAGE) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Niagen Bioscience and its competitors. This is 63% below median its historical median of 0.08. Over the past decade, Niagen Bioscience's Debt-to-Equity has ranged from 0.01 to 0.81. According to the industry distribution chart, Niagen Bioscience ranks #185 out of 956 companies in the Biotechnology industry, placing it in the top 19.4%.
Is Niagen Bioscience's Debt-to-Equity too high?
Niagen Bioscience's current Debt-to-Equity of 0.03 is 63% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.81. The Biotechnology industry median Debt-to-Equity is 0.16. Niagen Bioscience's value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Niagen Bioscience ranks #185 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Niagen Bioscience has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Debt-to-Equity compare to CAMP and ALEC?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #185 out of 956 companies for Debt-to-Equity. This places Niagen Bioscience in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Niagen Bioscience's value of 0.03 is 81.3% below this benchmark. Historically, Niagen Bioscience's own Debt-to-Equity has ranged from 0.01 to 0.81 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Niagen Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Debt-to-Equity is 0.03, which is 63% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (NAGE) is currently considered Possible Value Trap. The stock's GF Value™ is $4.96, compared to a current price of $3.13 — trading 36.9% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 63% below median its 10-year median of 0.08 and 81.3% below the Biotechnology industry median of 0.16. Niagen Bioscience's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Niagen Bioscience (NAGE), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (NAGE) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of $3.13 is trading 36.9% below its estimated GF Value™ of $4.96.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for NAGE:
Debt-to-Equity: 0.03 (63% below median its 10-year median of 0.08)
GF Value™: $4.96 vs. price of $3.13 (36.9% below fair value)
Industry Position: 81.3% below the Biotechnology median (#185 of 956)
No single metric tells the full story. See the NAGE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score
Get the complete analysis for NAGE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAGE has been successfully added to your 
